Specifically regulated genes in malignant melanoma tissues identified by subtractive hybridization

Por Hipfel, R, Schittek, B, Bodingbauer, Y, Garbe, C
Publicado em 2000

Expression of interleukin 10 in human melanoma.

Por Krüger-Krasagakes, S., Krasagakis, K., Garbe, C., Schmitt, E., Hüls, C., Blankenstein, T., Diamantstein, T.
Publicado em 1994

The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients.

Por Häffner, A. C., Garbe, C., Burg, G., Büttner, P., Orfanos, C. E., Rassner, G.
Publicado em 1992

Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma

Por Bauer, J, Kilic, E, Vaarwater, J, Bastian, B C, Garbe, C, de Klein, A
Publicado em 2009

Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors – Results of a Prospective Biomarker Study

Por Forschner A, Weißgraeber S, Hadaschik D, Schulze M, Kopp M, Kelkenberg S, Sinnberg T, Garbe C, Biskup S, Battke F
Publicado em 2020-06-01

Determinants of survival in patients with brain metastases from cutaneous melanoma

Por Staudt, M, Lasithiotakis, K, Leiter, U, Meier, F, Eigentler, T, Bamberg, M, Tatagiba, M, Brossart, P, Garbe, C
Publicado em 2010

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

Por Radny, P, Caroli, U M, Bauer, J, Paul, T, Schlegel, C, Eigentler, T K, Weide, B, Schwarz, M, Garbe, C
Publicado em 2003

Naturally Processed Dermcidin-Derived Peptides Do Not Permeabilize Bacterial Membranes and Kill Microorganisms Irrespective of Their Charge

Por Steffen, H., Rieg, S., Wiedemann, I., Kalbacher, H., Deeg, M., Sahl, H.-G., Peschel, A., Götz, F., Garbe, C., Schittek, B.
Publicado em 2006

Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis

Por Weide, B, Elsässer, M, Büttner, P, Pflugfelder, A, Leiter, U, Eigentler, T K, Bauer, J, Witte, M, Meier, F, Garbe, C
Publicado em 2012

Microarchitecture Is Severely Compromised but Motor Protein Function Is Preserved in Dystrophic mdx Skeletal Muscle

Por Friedrich, O., Both, M., Weber, C., Schürmann, S., Teichmann, M.D.H., von Wegner, F., Fink, R.H.A., Vogel, M., Chamberlain, J.S., Garbe, C.
Publicado em 2010

Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)

Por Hauschild, A, Garbe, C, Stolz, W, Ellwanger, U, Seiter, S, Dummer, R, Ugurel, S, Sebastian, G, Nashan, D, Linse, R, Achtelik, W, Mohr, P, Kaufmann, R, Fey, M, Ulrich, J, Tilgen, W
Publicado em 2001

Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study

Por Schadendorf, D., Amonkar, M. M., Milhem, M., Grotzinger, K., Demidov, L. V., Rutkowski, P., Garbe, C., Dummer, R., Hassel, J. C., Wolter, P., Mohr, P., Trefzer, U., Lefeuvre-Plesse, C., Rutten, A., Steven, N., Ullenhag, G., Sherman, L., Wu, F. S., Patel, K., Casey, M., Robert, C.
Publicado no Ann Oncol (2014)